Keywords: tracleer, shows, promise, class, ii, pah, patients

Tracleer shows promise in class II PAH patients

Article | 22 December 2006

Print This

Swiss pharmaceutical group Actelion says that initial data from a trial of its endothelin antagonist Tracleer (bosentan) indicate it has ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in